Treating a broad range of gram-positive bacterial infections
ACX-375C, our second program, is also a DNA polymerase IIIC inhibitor. ACX-375C targets the treatment of other gram-positive bacterial infections including those caused by MRSA, VRE and PRSP. These include patients with urinary tract infections, hospital acquired catheter/blood stream infections, intra-abdominal infections, skin and soft tissue infections, bone/joint infections, pneumonia, ear and sinus infections. The foregoing clinical indications constitute a completely different target customer group beyond patients with CDI which is treated by our lead antibiotic program.
|Enterococcus / VRE||Staph aureus / MRSA^||Strep pneumoniae / PRSP^^|
|ACX-375C MIC (μg/mL)||0.63-2.5||1.25-2.5||1.25-5.0|
|No. of US infections/yr*||66,000/20,000||~2,000,000/80,500||4,000,000/1,200,000|
|No. of US deaths/yr*||Unknown/1,300||Unknown/11,300||22,000/7,000|
|Main indications||Urinary tract, catheter/blood stream, intra-abdominal infections||Skin/soft tissue, hospital-acquired, bone/joint, catheter/bloodstream||Pneumonia, ear/sinus infections|